The novel drug under trial to counter antibiotic-resistant strains to treat UTIs in females

Published On: 17 Apr, 2023 9:24 PM | Updated On: 21 May, 2024 6:03 AM

The novel drug under trial to counter antibiotic-resistant strains to treat UTIs in females

British pharmaceutical giant GlaxoSmithKline (GSK) announced on Saturday that its new antibiotic drug, gepotidacin, has been successful in late-stage clinical trials for the treatment of uncomplicated urinary tract infections (uUTIs). The drug was found to be either equal to or better than the current standard of care, nitrofurantoin, for treating uUTIs in female adults and adolescents. GSK aims to propose its results for clinical approval crafting gepotidacin as a potentially viable and effective treatment option for uUTIs.

GSK is hoping to submit the results of its clinical trials to the United States Food and Drug Administration (FDA) for review sometime in the latter half of the second quarter. If approved, this new type of antibiotic would be the first of its kind in 20 years to treat urinary tract infections that have become resistant to existing antibiotics. This could be a major breakthrough in the fight against drug-resistant infections.

According to Chris Corsico, GSK's Senior Vice President of Development, “Gepotidacin could be a much-needed solution for those at risk of treatment failure due to antimicrobial resistance or recurrence of uUTIs.” GSK estimates that more than half of all women worldwide experience a uUTI at least once in their lifetime. If approved, Gepotidacin is expected to become a blockbuster drug, with non-risk adjusted peak year sales potentially reaching up to 1 billion pounds ($1.24 billion).

user
IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team
Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks